2-(4,5,6-trimethoxy-indol-3-yl)-ethylamine | 5376-34-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(4,5,6-trimethoxy-indol-3-yl)-ethylamine
• 英文别名: 2-(4,5,6-Trimethoxy-indol-3-yl)-aethylamin；4,5,6-trimethoxy-3-(2-aminoethyl)indole；2-(4,5,6-Trimethoxy-1H-indol-3-yl)-ethylamine；2-(4,5,6-trimethoxy-1H-indol-3-yl)ethanamine
• CAS: 5376-34-1
• 化学式: C₁₃H₁₈N₂O₃
• 分子量: 250.298
• InChiKey: MEHYOLHJCSYBTI-UHFFFAOYSA-N

物化性质

• 熔点：
  146-147 °C
• 沸点：
  423.7±40.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  69.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氟脲嘧啶 、 2-(4,5,6-trimethoxy-indol-3-yl)-ethylamine 在 N2 作用下， 以 吡啶 为溶剂， 生成 2H-pyrimidinecarboxamide
  参考文献：
  名称：

  5-fluoro-3,4-dihydro-2,4-dioxo-N-(3-indolyl)-1(2H)-pyrimidinecarboxamides

  摘要：

  本发明的5-氟尿嘧啶衍生物由下式表示：##STR1## 其中，R表示具有1-8个碳原子的烷基，A表示原子基团--NH--和--CO--，n为0或1，Y表示具有1-10个碳原子的烷基，芳基，杂环芳基，带有卤素作为配离子或异氰酸酯基的吡啶阳离子。这些衍生物可作为抗癌药物及其中间体。这些衍生物由本发明的六种指定方法生产。代表性方法是一种过程，其中包括反应5-氟尿嘧啶和一个由下式表示的异氰酸酯：Y--(A)n--R--NCO（VII），其中R，A，n和Y与式（I）中所示的相同。

  公开号：

  US04792607A1

文献信息

• 5-Fluorouracil derivatives and processes for producing thereof
  申请人：Chisso Corporation

  公开号：EP0240352A2

  公开（公告）日：1987-10-07

  5-Fluorouracil derivatives of this invention are represented by a general formula: wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, A indicates an atomic group of -NH- and -CO-, n is 0 or 1, and Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group. These derivatives are useful as anticancer medicines and intermediates thereof and have lower toxicity than usual compounds. These derivatives are produced by specified six methods of this invention. Representative method is a process which comprises reacting 5-fluorouracil and an isocyanate represented by a general formula: Y - (A) n - R - NCO (VII) wherein R, A, n and Y are the same as those indicated in the formula (I).

  本发明的5-氟尿嘧啶衍生物由通式表示： 其中 R 表示具有 0-10 个碳原子的非取代或取代的亚烷基，A 表示 -NH- 和 -CO- 的原子团，n 为 0 或 1，Y 表示具有 1-10 个碳原子的非取代或取代的烷基、非取代或取代的芳基、非取代或取代的杂芳基、具有卤素作为配对离子的吡啶鎓离子或异氰酸酯基团。 这些衍生物可用作抗癌药物及其中间体，其毒性低于普通化合物。 这些衍生物是通过本发明指定的六种方法生产出来的。具有代表性的方法是将 5-氟尿嘧啶和由通式表示的异氰酸酯进行反应： Y - (A) n - R - NCO (VII) 其中 R、A、n 和 Y 与式（I）中所表示的相同。
• Melatonin Receptor Ligands:  Synthesis of New Melatonin Derivatives and Comprehensive Comparative Molecular Field Analysis (CoMFA) Study
  作者：Marco Mor、Silvia Rivara、Claudia Silva、Fabrizio Bordi、Pier Vincenzo Plazzi、Gilberto Spadoni、Giuseppe Diamantini、Cesarino Balsamini、Giorgio Tarzia、Franco Fraschini、Valeria Lucini、Romolo Nonno、Bojidar Michaylov Stankov

  DOI：10.1021/jm9810093

  日期：1998.9.1

  The CoMFA methodology was applied to melatonin receptor ligands in order to establish quantitative structure-affinity relationships. One hundred thirty-three compounds were considered: they were either collected from literature or newly synthesized in order to gain information about the less explored positions. To this end, various melatonin derivatives were prepared and their affinity for quail optic tecta melatonin receptor was tested. Compounds were aligned on the putative active conformation of melatonin proposed by our previously reported pharmacophore search, and their relative affinities were calculated from the displacement of 2-[I-125]-iodomelatonin on different tissues expressing aMT receptors. Compounds were grouped into three sets according to their topology. Subset A: melatonin-like compounds; subset B: N-acyl-2-amino-8-methoxytetralins and related compounds; subset C: N-acyl-phenylalkylamines and related compounds. CoMFA models were derived for each set, using the steric, electrostatic, and lipophilic fields as structural descriptors; the PLS analyses were characterized by good statistical parameters, taking into account the heterogeneity of the binding data, obtained with different experimental protocols. From the CoMFA model for the melatonin-like compounds, besides the well-known positive effect of 2-substitution, a low steric tolerance for substituents in 1, 6, and 7, and a negative effect of electron-rich 4-substituents were observed; the information provided by the newly synthesized compounds was essential for these results. Moreover, a comprehensive model for the 133 compounds, accounting for a common alignment and a common mode of interaction at the melatonin receptor, was derived (Q(2) = 0.769, R-2 = 0.905). This model validates our previously reported pharmacophore search and offers a clear depiction of the structure-affinity relationships for the melatonin receptor ligands.
• DE1143823
  申请人：——

  公开号：——

  公开（公告）日：——
• Balsamini; Spadoni; Duranti, Il Farmaco, 1989, vol. 44, # 4, p. 399 - 413
  作者：Balsamini、Spadoni、Duranti、Cerrini、Lamba、Fedeli

  DOI：——

  日期：——
• Velluz, Annales Pharmaceutiques Francaises, 1959, vol. 17, p. 15,21
  作者：Velluz

  DOI：——

  日期：——